Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Market Movers
TipRanks 50 Index
AI Stocks
Largest Companies by Market Cap
ETFs
Top ETFs by Upside
Top ETFs by Smart Score
Top Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Ideas
Plans
Research Tools
Trending Stocks
Compare Stocks
Compare ETFs
Trump Dashboard
New
Daily Feeds
Daily Analyst Ratings
Daily Insider Trading Tracker
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
FDA Calendar
Market Holidays
Calculators
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Economic Indicators
Inflation Rate
Unemployment Rate
Class Actions
Tools
Plans
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Screeners
Plans
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Dividends
Plans
My Experts
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Experts
Plans
Portfolio
Plans
Trending News
More News >
News
Plans
Private Companies
Plans
Enterprise Solutions
Plans
Education
Personal Finance
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Careers
Contact Us
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
MCP for Agents
Advertise with Us
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
More
Plans
Plans
Plans
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Screeners
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Ideas
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Research Tools
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Calculators
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
FDA Calendar
Market Holidays
Dividends
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Experts
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Market Movers
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Private Companies
Personal Finance
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
More
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Log Out
Advertisement
Advertisement
ATHE
Stock Latest News
Company Announcements
Alterity Therapeutics Data Underpin Phase 3 Advancement of ATH434 in Multiple System Atrophy
13d ago
6K
ATHE
Premium
Company Announcements
Alterity Therapeutics Files May 2026 Form 6-K, Releases New Corporate Presentation
20d ago
6K
ATHE
Premium
The Fly
Alterity Therapeutics publishes quantitative susceptibility mapping MRI data
21d ago
ATHE
Premium
Company Announcements
Alterity Therapeutics Highlights MRI Biomarker Breakthrough as It Prepares Phase 3 MSA Program
21d ago
6K
ATHE
Premium
The Fly
Alterity Therapeutics receives FDA feedback after second ATH434 Type C meeting
1M ago
ATHE
Premium
The Fly
Alterity Therapeutics presents new data analyses from ATH434 trial
1M ago
ATHE
Premium
The Fly
Alterity Therapeutics appoints Cunningham to Board of Directors
1M ago
ATHE
Premium
The Fly
Alterity Therapeutics receives regulatory feedback from FDA regarding ATH434
2M ago
ATHE
Premium
The Fly
Alterity Therapeutics appoints Daniel Claasen as chief medical advisor
3M ago
ATHE
Premium
The Fly
Alterity Therapeutics recognizes MSA Awareness Month
3M ago
ATHE
Premium
The Fly
Alterity Therapeutics recognizes MSA Awareness Month
3M ago
ATHE
Premium
The Fly
Alterity Therapeutics provides corporate update
4M ago
ATHE
Premium
The Fly
Alterity Therapeutics highlights key 2026 objectives
4M ago
ATHE
Premium
The Fly
Alterity Therapeutics initiated with a Speculative Buy at Canaccord
6M ago
ATHE
Premium
The Fly
Alterity ‘never lost sight’ of interest in Parkinson’s disease, CEO says
6M ago
ATHE
Premium
The Fly
Alterity CEO says to meet with FDA, move forward with Phase 3 study
6M ago
ATHE
Premium
The Fly
Alterity ‘really emerging’ as U.S. company, CEO tells The Fly
6M ago
ATHE
Premium
The Fly
Stamler says Alterity treating neurodegeneration in ‘way no one else is doing’
6M ago
ATHE
Premium
The Fly
Meet Alterity Therapeutics: Fly exclusive interview with CEO David Stamler
6M ago
ATHE
Premium
The Fly
Alterity Therapeutics presents analyses related to OH from ATH434-201 trial
7M ago
ATHE
Premium
The Fly
Alterity Therapeutics reports cash balance of A$54.46M as of September 30
7M ago
ATHE
Premium
Company Announcements
Alterity Therapeutics Reports Change in Substantial Holding by Regal Funds
8M ago
6K
ATHE
Show More
Trending
Indices
Stocks
ETFs
Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >
You need to enable JavaScript to run this app.
